Oragenics Inc (OGEN)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21

Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the...

Form 8-K - Current report

ORAGENICS PROVIDES INVESTOR UPDATE

A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Sarasota, FL, May 18, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc...

Form PRE 14A - Other preliminary proxy statements

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies...

Form 8-K - Current report

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

SARASOTA, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage...

Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation...

Form 8-K - Current report

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of...

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage...

Form EFFECT - Notice of Effectiveness